Biosimilar Growth Hormones Market Forecast Signals New Revenue Opportunities Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Biosimilar Growth Hormones Market Forecast Highlighting Growth From $0.97 Billion To $1.46 Billion
The biosimilar growth hormones sector has experienced swift expansion in recent years. Its valuation is projected to increase from $0.89 billion in 2025 to $0.98 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.1%. During the historical period, this growth was driven by several factors, including the elevated costs associated with branded growth hormone treatments, a rising incidence of growth hormone deficiency, an uptick in diagnoses of pediatric growth disorders, restricted availability of cost-effective therapeutic options, and a reliance on hospital-based administration methods.
The biosimilar growth hormones market is anticipated to experience robust expansion over the coming years, with projections indicating it will reach a value of $1.46 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.5%. This forecasted growth is driven by several factors, including the expiration of patents on branded growth hormones, a rising number of biosimilar approvals, the broadening of self-administration treatment options, greater public awareness of growth disorders, and increased healthcare spending in developing economies. Key developments shaping this period involve a growing shift toward more affordable biosimilar growth hormone products, heightened demand for therapies targeting both pediatric and adult patients, an increased preference for subcutaneous self-administration, the expansion of online pharmacies and specialized clinics, and a more favorable regulatory environment for biosimilars.
Download A Free Sample Report For Comprehensive Market Insights:
Biosimilar Growth Hormones Market Demand Drivers Creating New Revenue Opportunities
An increasing number of children affected by growth hormone deficiency is fueling the expansion of the global biosimilar growth hormone market. This condition arises from damage to the pituitary gland or hypothalamus, which can be caused either by an abnormal development occurring before birth (congenital) or by events that take place during or after childbirth (acquired). As an example, in September 2023, data from Hormones Australia, published by the Endocrine Society of Australia—a national body focused on managing endocrine conditions and diseases—indicated that growth hormone deficiency is estimated to impact 2 to 3 individuals per 10,000 people. Consequently, the rising prevalence of growth deficiencies among children is propelling growth within the biosimilar growth hormone industry.
Biosimilar Growth Hormones Market Segment Performance And Strategic Opportunities
The biosimilar growth hormones market covered in this report is segmented –
1) By Route Of Administration: Subcutaneous, Intramuscular, Oral
2) By Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications
3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics
Subsegments:
1) By Subcutaneous: Self-administration, Professional Administration
2) By Intramuscular: Pediatric Care, Adult Care
3) By Oral: Tablets, Capsules
Biosimilar Growth Hormones Market Trends Driving Strategic Industry Expansion
Major players in the biosimilar growth hormone market are developing innovative human growth hormone solutions aimed at improving both treatment effectiveness and accessibility for growth hormone deficiencies. These growth hormone solutions encompass medical treatments or supplements designed to stimulate or replace natural human growth hormone (HGH) in the body, addressing growth deficits or anti-aging concerns. For example, in June 2023, Pfizer Inc., a US-based pharmaceutical company, along with OPKO Health Inc., another US-based healthcare firm, secured approval from the US Food and Drug Administration (FDA) for NGENLA (somatrogon-ghla). This treatment is a once-weekly injectable human growth hormone specifically developed for pediatric patients suffering from growth hormone deficiency (GHD). By providing a long-acting alternative to daily injections, it significantly enhances adherence and convenience for both patients and their caregivers. The approval was informed by clinical trials that confirmed its efficacy and safety, representing a notable milestone in the evolution of growth hormone therapies.
Biosimilar Growth Hormones Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the biosimilar growth hormones market are Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners And LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., LG Chem Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., PlantForm Corporation
Access The Complete Biosimilar Growth Hormones Market Report:
Biosimilar Growth Hormones Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the biosimilar growth hormone market in 2025. The Middle East is expected to be the fastest-growing region in the biosimilar growth hormones market report during the forecast period. The regions covered in the biosimilar growth hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
